Clinical Trial Search

Primary: Percentage of Time During the 4-hour Post-dosing Period With pH Below pH 4 — 5.14; 14.94 percentage of time with pH below pH 4 — p=0.0003

Primary: Change From Baseline to Week 12 in ADAS-Cog11 — -2.32; -1.34; -3.01; -2.24 units on a scale

Primary: Percent Reduction in CTCAE Grade 2/3 Eosinophil-related Cutaneous Adverse Events — 32; 10; 9 Participants

Primary: Questionnaire About the Process of Recovery (QPR) Change — 48.3; 50.1 score on a scale — p=.05

Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.03 — 3; 3; 2; 0 Participants

Primary: Functional Outcome of Sleep Questionnaire - Short Form (FOSQ-10) — 1.96; 1.73 score on a scale — p=<0.0001

Primary: Hamilton Depression Rating Scale Score After Last Treatment — 12.0; 13.0 units on a scale — p=0.3

Primary: Number of Participants With Procedural Success — 14 Participants

Primary: Presence of Fecal Shedding of Polio Vaccine Virus Determined by Culture (Polio Trial) — 99; 109 Participants — p=0.4

Primary: Adherence — 7.3 number of sessions completed

Primary: Change From Baseline to Treatment for Constructive Engagement on the Menorah Park Engagement Scale — 0.83 score on a scale — p=<0.01

Primary: Number of Participants Classified According to Education Level at Index Date — 32; 1; 22; 85 Participants

Primary: Brief Pain Inventory (BPI) Total Pain Severity — 6.1; 5.7; 5.8 score on a scale

Primary: Self-reported HIV Testing — 65.6; 31.3 percentage of participants

Primary: Part A: Change From Baseline in Body Weight at Week 12 — NA; NA; NA; NA Kilogram